Insider Selling: AnaptysBio (NASDAQ:ANAB) CFO Sells 1,908 Shares of Stock

AnaptysBio, Inc. (NASDAQ:ANAB) CFO Dennis Mulroy sold 1,908 shares of AnaptysBio stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $45.11, for a total value of $86,069.88. Following the completion of the transaction, the chief financial officer owned 17,667 shares of the company’s stock, valued at approximately $796,958.37. The trade was a 9.75% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Dennis Mulroy also recently made the following trade(s):

• On Monday, January 5th, Dennis Mulroy sold 3,363 shares of AnaptysBio stock. The shares were sold at an average price of $43.26, for a total transaction of $145,483.38.
• On Monday, December 22nd, Dennis Mulroy sold 10,000 shares of AnaptysBio stock. The stock was sold at an average price of $50.00, for a total value of $500,000.00.
• On Tuesday, December 16th, Dennis Mulroy sold 15,725 shares of AnaptysBio stock. The stock was sold at an average price of $44.85, for a total value of $705,266.25.

AnaptysBio Price Performance

NASDAQ:ANAB traded down $1.41 during midday trading on Thursday, reaching $43.80. 1,747,008 shares of the company traded hands, compared to its average volume of 768,760. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of -15.53 and a beta of 0.32. The company has a fifty day moving average price of $42.31 and a 200 day moving average price of $31.22. AnaptysBio, Inc. has a twelve month low of $12.21 and a twelve month high of $52.47.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $1.58. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%.The company had revenue of $76.32 million for the quarter, compared to analysts’ expectations of $15.83 million. On average, equities research analysts forecast that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio announced that its Board of Directors has authorized a stock buyback plan on Friday, November 21st that permits the company to repurchase $100.00 million in outstanding shares. This repurchase authorization permits the biotechnology company to purchase up to 9.6% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on ANAB shares. Stifel Nicolaus cut their price target on AnaptysBio from $80.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday, December 11th. Wells Fargo & Company lifted their target price on AnaptysBio from $51.00 to $81.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AnaptysBio in a research report on Wednesday, October 8th. Barclays lowered their price target on AnaptysBio from $70.00 to $55.00 and set an “overweight” rating on the stock in a report on Wednesday, December 17th. Finally, Wall Street Zen upgraded shares of AnaptysBio from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 16th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, AnaptysBio presently has a consensus rating of “Moderate Buy” and an average target price of $60.40.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ANAB. Larson Financial Group LLC boosted its stake in shares of AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 473 shares in the last quarter. Bessemer Group Inc. lifted its holdings in shares of AnaptysBio by 950.0% during the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 1,292 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of AnaptysBio by 175.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 1,377 shares during the period. Osaic Holdings Inc. increased its stake in AnaptysBio by 11,630.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 2,326 shares in the last quarter. Finally, Profund Advisors LLC purchased a new position in AnaptysBio in the 3rd quarter worth about $201,000.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.